The AI in Pharma Summit has >2000 contacts who are fully or partially responsible for AI /Machine Learning in their organisation. (80% are working for a Big Pharma company). The annual survey is sent to these contacts, and responses are collected anonymously. This is a summary of the findings.
Here are some of the Headlines:
- There is a level of disparity of opinions within this industry.
- Pharma companies need to be more ruthless when deciding where to invest in AI/Machine Learning.
- Sentiment over the next 3 years is improving.
- Drug discovery has the greatest potential to make an impact in 5 years time.
Sentiment towards AI/Machine Learning
Respondents were asked to rate the current value of AI/Machine Learning in Pharma, and where they thought it would be in 3 years time.
1 = It isn’t achieving anything
10 = It’s solved all our problems.
For the present, the mean score was 3.2 compared to 5.8 for forecast sentiment in 3 years time. The mode was 2 for current sentiment, compared to 8 for the future. This is a marked change in sentiment predicted by 2021.
Current attitude towards investment
Respondents were asked a simple yes/no question and gave an unequivocal answer.
“Are Pharma companies being ruthless enough when deciding where to invest their efforts with AI/Machine Learning”
Results from a sample of 285 people working in Pharma and Biotechs in the field of AI/Machine Learning.
Copyright 2018 Grey Green Media Ltd